Loading...
ROCO
3184
Market cap34mUSD
Oct 08, Last price  
17.60TWD
1D
2.03%
1Q
11.75%
Jan 2017
-9.74%
IPO
-68.33%
Name

MicroBase Technology Corp

Chart & performance

D1W1MN
ROCO:3184 chart
P/E
36.83
P/S
5.24
EPS
0.48
Div yield, %
—
Shrs. gr., 5y
-4.17%
Rev. gr., 5y
-3.26%
Revenues
212m
-1.43%
0249,839,000212,861,000182,289,000194,751,000214,764,000211,699,000
Net income
30m
-56.59%
-4,900,000-73,962,000-37,350,0006,353,00038,105,00069,436,00030,140,000
CFO
40m
-43.19%
0-40,165,00012,124,00057,886,00037,403,00070,783,00040,212,000
Dividend
Jul 13, 20260.2214 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

MicroBase Technology Corp., founded in 1997 and headquartered in Taoyuan City, Taiwan, specializes in providing critical drug administration solutions to patients and medical professionals throughout Taiwan. A key area of their expertise involves pioneering the development of non-silicon-based Micro-Electro-Mechanical Systems (MEMS) by leveraging LIGA technology. This sophisticated method facilitates the engineering and production of extremely small devices and micron-sized components. Their product offerings include "Pocket Air," an innovative inhalation device designed to assist individuals with respiratory conditions, and "PharMatrix," a line of micro-needle products tailored for convenient at-home application by women.

Key people

Tianlai Liu
General Manager · since 2021
Zhengxing Gao
Chief Financial Officer, Deputy General Manager · since 2012
Peiying Hong
Head of Finance & Accounting · since 2021
Yuren Chen
Director · since 2021
Yaoyu Du
Director · since 2021
Xin Li
Chairman of the Board · since 2021
Zhongjie Ren
Director · since 2024
Deli Chen
Independent Director · since 2021
Liancong Huang
Independent Director · since 2021
IPO date
Apr 18, 2013
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT